TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02340130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DP/MG/14-1
Description: The administration regimen will consist of a rush build-up régimen and a follow up period

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DP/MG/14-2
Description: The administration regimen will consist of a rush build-up régimen and a follow up period
Study: NCT02472535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Run-In Period: Placebo
Description: 2 capsules, once a day for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 50 mg (Dose Escalation Period 1)
Description: 1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)
Description: 1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)
Description: 1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)
Study: NCT03559400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local gentamicin injection
Description: Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline injection
Description: Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
Study: NCT00719771

Intervention type: DEVICE
Group type: OTHER
Intervention: Global® AP™ Total shoulder arthroplasty
Description: Total shoulder arthroplasty
Study: NCT01151228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.
Description: Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.
Description: Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
Study: NCT03612063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch III and Garmin Vivosmart HR
Description: During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch III and TomTom Spark 3
Description: During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes
Study: NCT01546233

Intervention type: BEHAVIORAL
Intervention: multidisciplinary education programme
Description: Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.

Intervention type: BEHAVIORAL
Intervention: standard education
Description: standard education before and after chemotherapy
Study: NCT02505022

Intervention type: DRUG
Intervention: Pharmacotherapy
Description: Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.

Intervention type: BEHAVIORAL
Intervention: Behavioral treatment
Description: Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
Study: NCT01248728

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Description: Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
Study: NCT04338607

Intervention type: PROCEDURE
Intervention: Subtalar (Talocalcaneal) arthrodesis
Description: Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
Study: NCT01151228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.
Description: Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.
Description: Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.
Description: Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.
Description: Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
Study: NCT01877044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAXUS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAXUS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02425904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: second-generation purine nucleoside analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: second-generation purine nucleoside analog
Study: NCT04338607

Intervention type: DEVICE
Intervention: DynaNail Mini
Description: Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
Study: NCT02216916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM781-36B
Study: NCT03173989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosis Exercises Orientation
Description: Use of orthosis, exercises and orientation for home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orientation
Description: Orientation for home.
Study: NCT01141998

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium, Dietary
Description: 400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium, Dietary
Description: 400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium, Dietary
Description: 400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 38 micrograms daily. Week 0-10.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVB
Description: Ultraviolet radiation type B administered in a tanning bed. One time weekly.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: UV-filtered light.
Description: Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UV-filtered light.
Description: Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 38 micrograms daily. From week 14 to 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 38 micrograms daily. From week 14 to 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 38 micrograms daily. From week 14 to 52.
Study: NCT03531840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: All subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClinOmics
Description: Non-significant risk (NSR) device
Study: NCT04328155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hotpack Group
Description: Hotpack Group received 20 minutes hotpack to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrared Group
Description: Infrared Group received 20 minutes infrared to hamstring muscles region at prone position and participants stretchted the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15. seconds .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Group
Description: Ultrasound Group received 5 minutes 1 M-Hz, 1,5 watt/cm2 ultrasound therapy to hamstring muscles region at prone position and participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control Group participants stretched the hamstring muscles at supine position.Self stretching hamstring exercise was done by straight leg lifting using a band three times for 15 seconds .
Study: NCT01671449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 : 40 mg/m2, twice daily, Day 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 : 40 mg/m2, twice daily, Day 1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 60 mg/m2/day Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2/day Day 1
Study: NCT01821066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991 alone
Description: PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 60 mg
Description: On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Description: On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991 combination
Description: PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
Study: NCT03833557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanohydroxyapatite Pulpotomy
Description: Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA pulpotomy
Description: Angleus grey MTA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol Pulpotomy
Description: Buckley's Fromocresol. diluted full strength foromocresol
Study: NCT01978145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSC
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSC
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
Study: NCT05107063

Intervention type: DRUG
Intervention: Pravastatin
Description: Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
Study: NCT04051294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercial kombucha tea
Description: Commercially-available kombucha tea.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brewed kombucha tea
Description: Kombucha tea brewed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Tea
Description: Tea brewed in our lab.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control: Water
Description: Tap water
Study: NCT01032187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: 20mg/kg/day IV for 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B-deoxycholate
Description: Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
Study: NCT02044224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required
Study: NCT03226327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula salt with very low sodium (Brand name: Manlikang)
Description: hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
Study: NCT04090957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol oral tablet
Description: Estetrol oral tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol oral tablet
Description: Estetrol oral tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol oral tablet
Description: Estetrol oral tablet will be administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet will be administered orally once daily.
Study: NCT03950544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Fosfomycin and meropenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Tigecycline and meropenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polymyxin B
Description: Polymyxin B and meropenem
Study: NCT02873455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short video clip including the circumstance of operation theater, and surgeon's interview
Study: NCT03388216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: INM004 Dose 1
Description: Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: INM004 Dose 2
Description: Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Drug: INM004- Repeated dose
Description: Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo infusion will be administered at the same infusion rate as the Drug arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo infusion will be administered at the same infusion rate as the Drug arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo infusion will be administered at the same infusion rate as the Drug arm
Study: NCT02072018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H-100
Description: H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
Study: NCT02361918

Intervention type: PROCEDURE
Intervention: Colon surgery

Intervention type: PROCEDURE
Intervention: Colon surgery
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet
Study: NCT02072018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
Study: NCT02165215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Participants will receive 105 mg etrolizumab SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Participants will receive 105 mg etrolizumab SC injection Q4W.
Study: NCT03687242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR001
Description: Open label SPR001
Study: NCT02165215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet
Study: NCT02565875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLL Presentation
Description: Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
Study: NCT03934203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet
Study: NCT02565875

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Presentation
Description: Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simulated laparoscopic task
Description: Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated laparoscopic task
Description: Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.